Biozep AS is a Norwegian biopharmaceutical company discovering and developing novel drugs for severe eye diseases. Biozep focuses on eye diseases which can lead to vision impairment and vision loss and with a high unmet medical need like age-related macular degeneration (AMD) and diabetic retinopathy (DR).

​​Our drug substances are based on a proprietary drug molecule platform called Target Optimized Lipids (TOLi), and we have more than 20 years of experience in identifying and validating druggable targets using the TOLi-platform.

​By using our novel TOLi-platform, Biozep has discovered substances with great potential in treatment of eye diseases. We have identified a lead compound based on its potent retina protective and anti-inflammatory effect documented by convincing in vitro data.  The company will during 2018 initiate proof of concept studies in animal models.